Get Your MMJ Card

Medical Marijuana for 

Glaucoma

Medical Marijuana for Glaucoma: What the Research Actually Shows

Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making changes to your treatment plan. Medical marijuana laws vary by state — verify the rules in your jurisdiction before proceeding.

Introduction

Glaucoma holds a unique place in the history of medical cannabis. It was one of the very first conditions for which the federal government granted compassionate use of marijuana in the United States — as early as the 1970s — and it remains one of the most commonly cited qualifying conditions in state medical marijuana programs today.

The scientific basis for that early recognition is real. Cannabis and THC have been shown in multiple clinical studies to reduce intraocular pressure (IOP) — the primary risk factor for glaucomatous optic nerve damage — comparably to many first-line glaucoma medications. Research going back to 1971 consistently demonstrates this effect.

But glaucoma is also where the medical cannabis story becomes most nuanced. The American Academy of Ophthalmology does not endorse cannabis as a primary or adjunctive glaucoma treatment — primarily because of one critical pharmacological limitation: the IOP-lowering effect lasts only three to four hours.

This article gives you the full, honest picture — the genuine promise of cannabinoids for glaucoma, the significant clinical limitations, the emerging science of neuroprotection and optic blood flow, and what this means for patients exploring their options.

What Is Glaucoma?

Glaucoma is a group of progressive eye disorders characterised by damage to the optic nerve — the bundle of over one million nerve fibres that transmits visual information from the retina to the brain. This damage produces characteristic visual field defects that begin in peripheral vision and progress, without treatment, toward total blindness.

Glaucoma is the second leading cause of irreversible blindness globally after cataracts (StatPearls, 2024) and the most common neurodegenerative disease in the world. It is silent in its early stages — most people with glaucoma have no symptoms until significant, irreversible vision loss has already occurred.

Scale of the condition

  • More than three million Americans are living with glaucoma, 2.7 million of whom have its most common form, primary open-angle glaucoma (National Glaucoma Research, 2026)
  • Currently affecting over 60 million people worldwide, projected to exceed 110 million by 2040 (StatPearls, 2024)
  • Glaucoma is the leading cause of blindness in African Americans and Hispanic Americans in the United States
  • A 2024 study in JAMA Ophthalmology provides the most current US prevalence estimates, confirming its status as a major and growing public health burden
  • Just under half (44.2%) of glaucoma patients surveyed at University of Minnesota eye clinics (2025) expressed interest in using marijuana for their glaucoma — reflecting persistent and substantial patient interest that demands informed clinical engagement

Types of glaucoma

Primary open-angle glaucoma (POAG) is the most common form, accounting for approximately 95% of cases. It develops gradually and painlessly as the eye’s drainage system becomes less efficient, allowing aqueous humour to accumulate and IOP to rise.

Normal-tension glaucoma (NTG) — comprising 30–90% of POAG cases depending on the population studied — is where IOP remains within the statistically normal range yet optic nerve damage progresses. In NTG, vascular insufficiency (inadequate blood flow to the optic nerve) is believed to play an equal or greater role than mechanical pressure. This distinction is critical for understanding why cannabinoids’ effects on ocular blood flow are particularly relevant for this patient population.

Angle-closure glaucoma occurs when the drainage angle is physically blocked. Acute angle-closure glaucoma is a medical emergency — sudden severe eye pain, nausea, vomiting, and blurred vision requiring immediate treatment.

Secondary glaucoma results from an identifiable underlying cause such as eye injury, corticosteroid medication, or other ocular disease.

How glaucoma damages vision

Elevated IOP compresses the lamina cribrosa — the sieve-like structure at the optic nerve head — impairing axonal transport and starving retinal ganglion cells of nutrients and cellular signals. This triggers irreversible neurodegeneration. In normal-tension glaucoma, vascular insufficiency drives retinal ganglion cell death even without pressure elevation.

Current treatments and their limitations

All currently approved glaucoma treatments work by reducing IOP: prostaglandin analogues (latanoprost, bimatoprost), beta-blockers (timolol), carbonic anhydrase inhibitors (dorzolamide), alpha-2 agonists (brimonidine), Rho-kinase inhibitors (netarsudil), laser therapy, and surgical procedures.

Despite these options, many patients continue to experience progressive optic nerve damage and visual field loss even with substantial IOP reduction. As the American Glaucoma Society noted in 2025, there is a strong unmet need for neuroprotective agents that can preserve retinal ganglion cells beyond IOP control alone.

The Endocannabinoid System and the Eye

The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein throughout ocular tissues including the ciliary body (which produces aqueous humour), the trabecular meshwork (which drains it), the retina, and the optic nerve head (Porcella et al., 2000). CB2 receptors are expressed in retinal microglia and immune cells.

This anatomical distribution has direct pharmacological implications:

  • Ciliary body CB1 activation reduces aqueous humour production — the same mechanism targeted by beta-blockers and carbonic anhydrase inhibitors
  • Trabecular meshwork CB1 activation may enhance aqueous humour outflow — complementing the mechanism of prostaglandin analogues
  • Retinal ganglion cell CB1/CB2 receptors position the ECS as a potential neuroprotective system acting independently of IOP

The eye’s rich cannabinoid receptor expression is not incidental — it places the ECS at the centre of the biological processes that go wrong in glaucoma.

The Clinical Evidence: IOP Reduction

The foundational research

The link between cannabis and reduced IOP was first reported by Hepler and Frank in a landmark 1971 paper, who observed that smoking cannabis lowered IOP by an average of 25–30% in healthy volunteers. This was replicated multiple times throughout the 1970s and triggered the first federal compassionate use authorisations for glaucoma patients in the United States.

What the modern evidence confirms

The IOP-lowering effect of THC is well-established and consistent across decades of research:

  • Clinical studies demonstrate IOP reduction in 60–65% of patients, with effects comparable to many FDA-approved glaucoma medications
  • A 2024 clinical trial demonstrated a statistically significant 14% IOP reduction with low-dose sublingual THC (P=0.026)
  • Standardised pharmaceutical cannabis preparations (Bedrocan) have documented IOP reductions of approximately 20% from baseline
  • MacMillan et al. (2019) reported an average IOP decrease of 6.6 mmHg at 90 minutes — a clinically meaningful reduction

The mechanism: THC activates CB1 receptors in the ciliary body, reducing cyclic AMP production and thereby decreasing aqueous humour production, while also reducing vascular resistance in the anterior uvea.

The critical limitation: duration

The IOP-lowering effect of cannabis lasts approximately three to four hours after administration.

Effective glaucoma management requires sustained 24-hour IOP control. The optic nerve is most vulnerable during overnight IOP peaks. A treatment that reduces IOP for three to four hours leaves twenty or more hours unprotected — and may create pressure rebounds after each dose wears off.

To provide adequate 24-hour IOP control using cannabis alone, a patient would need to dose six to eight times per day and night — an approach that is clinically impractical, incompatible with cognitive function, and associated with tolerance development, cardiovascular effects, and chronic psychoactive impairment.

This is why the American Academy of Ophthalmology does not endorse cannabis as a primary glaucoma treatment despite acknowledging the IOP-lowering evidence.

CBD and IOP — a critical caveat for glaucoma patients

One of the most important findings in recent glaucoma research is that CBD does not lower IOP and may in some patients actually raise it.

A landmark 2018 study by Miller et al. in Investigative Ophthalmology & Visual Science found that while THC lowered IOP in mice, CBD raised IOP — and co-administration of CBD alongside THC partially blocked THC’s IOP-lowering effect. This has been replicated and confirmed in human studies between 2020 and 2025.

The clinical implication is direct and important: for glaucoma patients, CBD-dominant products are not beneficial for IOP management and may be counterproductive. This is a significant departure from general cannabis medicine recommendations — glaucoma is the one major condition where CBD is not the safer default choice. The pharmacologically relevant cannabinoid for IOP reduction is THC.

Beyond IOP: The Emerging Science of Neuroprotection and Ocular Blood Flow

The most scientifically compelling and clinically important emerging research moves beyond IOP to address the two other pathways of glaucomatous damage: neurodegeneration and vascular insufficiency.

Neuroprotection of retinal ganglion cells

Retinal ganglion cells are the neurons destroyed in glaucoma and their loss is irreversible. No current approved glaucoma treatment protects these cells — they only reduce the IOP that damages them. A neuroprotective agent that could slow or halt retinal ganglion cell death independently of IOP would represent a major therapeutic breakthrough.

Preclinical research consistently demonstrates cannabinoid neuroprotection in retinal models. THC and CBD both reduce oxidative stress and excitotoxic damage to retinal ganglion cells in animal studies. CB1 and CB2 receptor activation reduces retinal glutamate-induced excitotoxicity — one of the key mechanisms of retinal ganglion cell death under elevated IOP conditions.

Results from a 2025 study indicate cannabinoids could offer some retinal protection from damage related to high pressure, though more evidence in human trials is needed before this translates into clinical practice.

Cannabinol (CBN) has emerged as a minor cannabinoid of particular interest for glaucoma neuroprotection. 2025 research demonstrates that CBN shows 33-hour retention in ocular tissues after injection — a pharmacokinetic profile that would allow sustained neuroprotection between infrequent doses, potentially addressing the duration problem that undermines THC’s utility for IOP management.

Ocular blood flow and normal-tension glaucoma

For normal-tension glaucoma patients — where vascular insufficiency drives optic nerve damage alongside or instead of elevated IOP — the vascular effects of cannabinoids are particularly clinically relevant.

A 2024 randomised clinical trial examining dronabinol (synthetic THC) in primary open-angle glaucoma patients found that a single dose significantly increased optic nerve head blood flow without compromising its autoregulatory capacity — while having no effect on IOP itself. CB1 and CB2 receptor activation enhances optic nerve perfusion through inhibition of endothelin-1, a potent vasoconstrictor. For NTG patients not achieving adequate control through conventional IOP-lowering alone, this vascular mechanism warrants serious clinical discussion.

Novel delivery systems

2024 research is advancing topical ocular delivery formulations designed to overcome the duration and psychoactivity limitations of systemic cannabis. Nanoparticle-based THC eye drops with 300% improved corneal penetration and 8-hour sustained release formulations are in preclinical and early clinical development. No topical cannabinoid formulation is yet approved for glaucoma, but this is an actively evolving research front.

Critically: crude cannabis extracts applied directly to the eye are not effective and can cause serious irritation. Corneal penetration requires specialised pharmaceutical formulation — this cannot be achieved with dispensary products.

Practical Guidance for Glaucoma Patients Using Cannabis

Role of cannabis in current glaucoma management

Given the duration limitation, cannabis is unlikely to replace conventional glaucoma medication as standalone IOP control. However, it may play a role as:

  • Adjunctive therapy when IOP is inadequately controlled on conventional medications alone
  • A neuroprotective agent for patients with progressive optic nerve damage despite controlled IOP — particularly as CBN research matures
  • A vascular agent for normal-tension glaucoma patients where improved optic nerve blood flow is the treatment goal
  • Symptom management for associated pain, sleep disruption, and anxiety in patients with advanced glaucoma

The IOP monitoring disclosure requirement

Cannabis temporarily lowers IOP, which can confound clinical measurements — potentially leading to missed diagnoses or a false impression of effective IOP control. Among 134 eye clinic patients surveyed at the University of Minnesota (2025), 15.7% reported recent marijuana use, 8.2% described themselves as regular users, and 4.5% used it daily — yet many had not disclosed this to their ophthalmologist.

Any glaucoma patient using cannabis must inform their ophthalmologist. Avoid cannabis in the hours before scheduled IOP measurements to ensure accurate clinical readings.

Product selection for glaucoma

  • Choose THC-containing products, not CBD-dominant — CBD does not help IOP and may worsen it
  • Sublingual tinctures provide faster, more predictable absorption than oral capsules — relevant for timing doses
  • Vaporisation provides fastest onset but shortest duration and most variable dosing
  • Avoid crude cannabis extracts applied to the eye — these are ineffective and dangerous

Does Glaucoma Qualify for a Medical Marijuana Card?

Glaucoma is one of the original qualifying conditions in US medical marijuana programs, with a history predating all state programs — the federal compassionate use programme of the 1970s was partly built around glaucoma patients.

As of 2026, glaucoma appears explicitly on the qualifying condition list in virtually every state with an active MMJ program. It is among the least contested qualifying conditions to establish, given its historical role in legitimising medical cannabis access.

Step-by-step qualification

Step 1: Confirm glaucoma is listed in your state using our state-by-state guide.

Step 2: Gather your ophthalmic records — IOP measurements, visual field test results, optic nerve imaging (OCT), and current medications. Documentation of inadequate IOP control or medication intolerance strengthens your application.

Step 3: Schedule a telehealth MMJ consultation via NuggMD, Leafwell, or Veriheal. The appointment takes 15–20 minutes. Describe your diagnosis, treatment history, current IOP levels, and what you are hoping cannabis may address.

Step 4: Receive your recommendation and register with your state if required.

Step 5 — Critical: Inform your ophthalmologist. For glaucoma specifically this is not optional — cannabis affects IOP measurements, may interact with eye drop medications, and your ophthalmologist must monitor disease progression with full knowledge of your treatment regimen.

Frequently Asked Questions

Can marijuana replace my glaucoma eye drops?
No — this would be medically inadvisable. Conventional glaucoma medications provide 24-hour IOP control; cannabis provides 3–4 hours. Replacing proven IOP-lowering therapy with cannabis alone risks inadequately controlled pressure and accelerated optic nerve damage. Any changes to your regimen must be made with your ophthalmologist’s involvement and with close monitoring.

Does CBD help glaucoma?
Current evidence indicates CBD does not lower IOP and may raise it. CBD-dominant products are not recommended for IOP management in glaucoma — which is a unique departure from general cannabis medicine guidance. Discuss with your ophthalmologist before using any cannabinoid product.

What about cannabis eye drops?
No cannabis eye drops are currently approved or commercially available. Pharmaceutical-grade topical cannabinoid formulations are in research and early clinical development, but crude cannabis extracts applied to the eye are ineffective and potentially harmful.

Is normal-tension glaucoma a qualifying condition?
Yes — it falls under the glaucoma category in all state MMJ programs. NTG patients may have particular reasons to discuss cannabinoids given the emerging evidence for vascular effects on optic nerve blood flow in this subtype.

Does cannabis use affect my glaucoma monitoring?
Yes — significantly. Cannabis temporarily lowers IOP, so measurements taken after cannabis use will not accurately reflect your true baseline. Always tell your ophthalmologist you use cannabis and avoid using it for several hours before scheduled IOP measurements.

Key Takeaways

  • Cannabis and THC reliably lower IOP — this is supported by over 50 years of research and produces reductions comparable to many approved medications
  • The critical limitation is duration: the effect lasts 3–4 hours, making cannabis impractical as standalone 24-hour IOP control at the frequency required
  • CBD does not lower IOP and may raise it — glaucoma patients should avoid CBD-dominant products for IOP management, a unique departure from general cannabis medicine guidance
  • Emerging research on cannabinoid neuroprotection (particularly CBN’s 33-hour ocular tissue retention) and optic nerve blood flow enhancement represents the most clinically compelling new direction
  • Normal-tension glaucoma patients — driven more by vascular insufficiency than pressure — may be a particular target population for cannabinoid vascular effects
  • Glaucoma qualifies for medical marijuana in virtually every US state with an active MMJ program
  • All glaucoma patients using cannabis must disclose this to their ophthalmologist — it affects IOP measurements and must be factored into clinical monitoring

Sources and Further Reading

  1. Hepler, R.S. & Frank, I.R. (1971). Marihuana smoking and intraocular pressure. JAMA, 217(10), 1392. https://doi.org/10.1001/jama.1971.03190100074024
  2. Miller, S., Daily, L., Leishman, E., Bradshaw, H., & Straiker, A. (2018). Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure. Investigative Ophthalmology & Visual Science, 59(15), 5904–5911. https://doi.org/10.1167/iovs.18-24838
  3. Adamek, A.J., Hussein, M.A., Abdulkarim, I., Orengo-Nania, S., & Sheheitli, H. (2025). Cannabis use in eye clinic patients and implications for glaucoma diagnosis. International Ophthalmology. https://doi.org/10.1007/s10792-025-03846-2
  4. Passani, A., Posarelli, C., Sframeli, A.T., et al. (2020). Cannabinoids in glaucoma patients: The never-ending story. Journal of Clinical Medicine, 9(12), 3978. https://doi.org/10.3390/jcm9123978
  5. PMC. Therapeutic Potential of Cannabinoids in Glaucoma. https://pmc.ncbi.nlm.nih.gov/articles/PMC10460067/
  6. StatPearls — NCBI Bookshelf (2024). Glaucoma. https://www.ncbi.nlm.nih.gov/books/NBK538217/
  7. StatPearls — NCBI Bookshelf. Cannabis Use for Glaucoma and Associated Pain. https://www.ncbi.nlm.nih.gov/books/NBK572112/
  8. Eyes on Eye Care (2025). Glaucoma Now: The Latest in Prevalence and Progression. https://eyesoneyecare.com/resources/glaucoma-latest-in-prevalence-progression/
  9. American Glaucoma Society-American Academy of Ophthalmology (2025). Position Statement on Glaucoma Neuroprotection. Ophthalmology Glaucoma. https://doi.org/10.1016/j.ogla.2025.01.001
  10. Ehrlich, J.R., et al. (2024). Prevalence of Glaucoma Among US Adults in 2022. JAMA Ophthalmology. https://doi.org/10.1001/jamaophthalmol.2024.3884
  11. National Glaucoma Research — Bright Focus Foundation (2026). Facts & Figures. https://www.brightfocus.org/glaucoma/facts-figures/
  12. Porcella, A., Maxia, C., Gessa, G.L., & Pani, L. (2000). The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein. European Journal of Neuroscience, 12(3), 1123–1127. https://doi.org/10.1046/j.1460-9568.2000.00979.x
  13. NCBI Bookshelf. Marijuana and Glaucoma — Marijuana as Medicine? https://www.ncbi.nlm.nih.gov/books/NBK224386/
  14. University of Utah Health (2025). Glaucoma and Cannabis: What Ophthalmologists Want You to Know. https://healthcare.utah.edu/healthfeed/2025/05/glaucoma-and-cannabis-what-ophthalmologists-want-you-know

This article was written and medically reviewed in March 2026. It will be updated as new research becomes available. For state-specific qualifying condition information, see our How to Get Your MMJ Card guide.